We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $8.69, marking a +1.4% move from the previous day. The stock's change was more than the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%.
Prior to today's trading, shares of the infectious disease drug developer had gained 4% outpaced the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $0.82 per share and a revenue of $535 million, demonstrating changes of +36.67% and +4.87%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.38% decrease. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now.
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 10.45. This signifies a discount in comparison to the average Forward P/E of 21.4 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 156, positioning it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $8.69, marking a +1.4% move from the previous day. The stock's change was more than the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%.
Prior to today's trading, shares of the infectious disease drug developer had gained 4% outpaced the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. In that report, analysts expect Adma Biologics to post earnings of $0.16 per share. This would mark year-over-year growth of 6.67%. Meanwhile, our latest consensus estimate is calling for revenue of $125.77 million, up 3.11% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $0.82 per share and a revenue of $535 million, demonstrating changes of +36.67% and +4.87%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.38% decrease. Adma Biologics is holding a Zacks Rank of #5 (Strong Sell) right now.
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 10.45. This signifies a discount in comparison to the average Forward P/E of 21.4 for its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 156, positioning it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.